Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
10.1158/1078-0432.ccr-18-2380 Clin
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
In April 2026, the FDA published a formal proposal in the Federal Register to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list, with a public comment period open through June 2026
In this particular case, were providing additional access to beneficiaries who wouldnt otherwise be covered by Medicare for obesity indications, and so theres access to additional patients who could really benefit from these medications, and thats mutually beneficial for both the taxpayer, for those beneficiaries, as well as for the companies
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine , 30 May 2025, Locatelli, Joo Carlos, et al
Moreover, a phase 1 study has shown that retatrutide may decrease appetite and increase sensation of fullness and satiety in patients with type 2 diabetes [2]
